 |
[Photo provided by L&C Bio Inc.] |
L&C Bio Inc., a South Korean research and development company specializing in tissue regeneration medicine, will list shares on the country’s secondary Kosdaq market next month with hopes to raise 20 billion won ($17.7 million).
According to multiple sources from the investment bank industry, L&C Bio plans to issue new shares at a price band of between 18,000 won and 20,000 won apiece, allowing the company to raise 20 billion won based on the top end price. L&C Bio is scheduled to hold a two-day book building session on October 16-17. Subscription for retail investors will take place on October 23-24 before shares debut on November 1. The deal is jointly led by Korea Investment & Securities Co. and DB Financial Investment Co.
L&C Bio - founded in 2011 - is engaged in the manufacturing and sales of tissue engineering medicines based on human tissue such as skin, bone, and cartilage.
There are currently four major options for patients with heavily damaged skin from burns to transplant skin tissue - transplanting the patient’s own skin, transplanting skin of a specially-raised animal, transplanting chemosynthetic fibrous tissue, or transplanting human tissue-derived grafting material. L&C Bio produces grafting material using human tissues, which triggers less immuno-rejection but results to effective and stable skin regeneration, the company said.
L&C Bio’s major product is MegaDerm - a skin transplantation material derived from human skin using AlloClean technology. L&C Bio is the country’s largest skin transplantation material producer, dominating a 45 percent market share. The development of L&C Bio’s MegaDerm using indigenous technology has led Korea to become less dependent on imported materials for skin transplantation.
L&C Bio also produces bone grafting material MegaBone and medical devices MegaDBM and anti-adhesive agent Megashield. The company raised 17.9 billion won in sales last year, up from 9 billion won in 2015. Its sales already reached 10.3 billion won in the first six months of this year.
[ⓒ Maeil Business Newspaper & mk.co.kr, All rights reserved]
이 기사의 카테고리는 언론사의 분류를 따릅니다.
기사가 속한 카테고리는 언론사가 분류합니다.
언론사는 한 기사를 두 개 이상의 카테고리로 분류할 수 있습니다.
언론사는 한 기사를 두 개 이상의 카테고리로 분류할 수 있습니다.
